Autolus Therapeutics (AUTL) Competitors $2.22 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends AUTL vs. EWTX, AMRX, KYMR, JANX, ARWR, NAMS, PTGX, VERA, CGON, and MIRMShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Edgewise Therapeutics (EWTX), Amneal Pharmaceuticals (AMRX), Kymera Therapeutics (KYMR), Janux Therapeutics (JANX), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), Protagonist Therapeutics (PTGX), Vera Therapeutics (VERA), CG Oncology (CGON), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Edgewise Therapeutics Amneal Pharmaceuticals Kymera Therapeutics Janux Therapeutics Arrowhead Pharmaceuticals NewAmsterdam Pharma Protagonist Therapeutics Vera Therapeutics CG Oncology Mirum Pharmaceuticals Edgewise Therapeutics (NASDAQ:EWTX) and Autolus Therapeutics (NASDAQ:AUTL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment. Do analysts recommend EWTX or AUTL? Edgewise Therapeutics currently has a consensus price target of $43.17, indicating a potential upside of 64.38%. Autolus Therapeutics has a consensus price target of $10.40, indicating a potential upside of 368.47%. Given Autolus Therapeutics' higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Edgewise Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor EWTX or AUTL? In the previous week, Autolus Therapeutics had 3 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for Autolus Therapeutics and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.43 beat Autolus Therapeutics' score of 0.43 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer EWTX or AUTL? Autolus Therapeutics received 193 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. However, 73.91% of users gave Edgewise Therapeutics an outperform vote while only 67.96% of users gave Autolus Therapeutics an outperform vote. CompanyUnderperformOutperformEdgewise TherapeuticsOutperform Votes3473.91% Underperform Votes1226.09% Autolus TherapeuticsOutperform Votes22767.96% Underperform Votes10732.04% Which has more risk and volatility, EWTX or AUTL? Edgewise Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Do insiders & institutionals believe in EWTX or AUTL? 72.8% of Autolus Therapeutics shares are owned by institutional investors. 24.1% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, EWTX or AUTL? Edgewise Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$100.16M-$1.50-17.51Autolus Therapeutics$1.70M347.48-$208.38M-$1.21-1.83 Is EWTX or AUTL more profitable? Edgewise Therapeutics' return on equity of -26.83% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -26.83% -25.67% Autolus Therapeutics N/A -63.65%-36.54% SummaryAutolus Therapeutics beats Edgewise Therapeutics on 9 of the 15 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$590.72M$2.96B$5.35B$9.06BDividend YieldN/A1.94%5.13%4.02%P/E Ratio-1.8345.5689.4817.34Price / Sales347.48358.881,251.39134.53Price / CashN/A192.9043.7535.97Price / Book3.473.975.324.80Net Income-$208.38M-$41.02M$122.60M$224.91M7 Day Performance-5.93%8.62%0.88%1.90%1 Month Performance-3.06%10.70%4.81%5.08%1 Year Performance-64.87%5.54%27.90%21.15% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics3.1524 of 5 stars$2.22flat$10.40+368.5%-65.8%$590.72M$1.70M-1.83330Short Interest ↑News CoverageGap DownEWTXEdgewise Therapeutics1.9138 of 5 stars$25.36+5.0%$43.17+70.2%+161.6%$2.40BN/A-16.9160Short Interest ↑Positive NewsGap DownAMRXAmneal Pharmaceuticals3.0287 of 5 stars$7.72-3.1%$10.00+29.5%+57.6%$2.39B$2.68B-11.357,700Short Interest ↓News CoverageKYMRKymera Therapeutics2.7199 of 5 stars$36.49-4.4%$55.38+51.8%+46.0%$2.36B$87.56M-15.59170News CoverageJANXJanux Therapeutics3.6545 of 5 stars$44.29-5.3%$89.90+103.0%+329.1%$2.32B$13.05M-37.8530Short Interest ↑ARWRArrowhead Pharmaceuticals4.2076 of 5 stars$18.59+0.5%$43.33+133.1%-42.6%$2.31B$3.55M-3.70400NAMSNewAmsterdam Pharma2.6616 of 5 stars$24.81-0.6%$38.17+53.8%+40.6%$2.29B$33.59M0.004Analyst ForecastPTGXProtagonist Therapeutics3.0945 of 5 stars$36.75+0.4%$53.78+46.3%+49.1%$2.19B$323.80M13.82125News CoveragePositive NewsVERAVera Therapeutics2.2943 of 5 stars$34.33-7.3%$63.50+85.0%+113.1%$2.17BN/A-13.1540CGONCG Oncology1.2445 of 5 stars$28.54-5.5%$63.88+123.8%N/A$2.17B$684,000.000.0061Short Interest ↑MIRMMirum Pharmaceuticals4.0294 of 5 stars$43.52+5.3%$57.10+31.2%+75.2%$2.09B$307.03M-21.54140News Coverage Related Companies and Tools Related Companies Edgewise Therapeutics Competitors Amneal Pharmaceuticals Competitors Kymera Therapeutics Competitors Janux Therapeutics Competitors Arrowhead Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Protagonist Therapeutics Competitors Vera Therapeutics Competitors CG Oncology Competitors Mirum Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AUTL) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
